Evidence map›Paper›PMID 25790332›Full record

ArticleBiochemistry2015

Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism.

Corina Rosales, Niket Patel, Baiba K Gillard, Dedipya Yelamanchili, Yaliu Yang, Harry S Courtney, Raul D Santos, Antonio M Gotto, Henry J Pownall

Abstract read
In one paragraph

Article in Biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Corina Rosales†Laboratory of Atherosclerosis and Lipoprotein Research, Department of Cardiology, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Niket Patel†Laboratory of Atherosclerosis and Lipoprotein Research, Department of Cardiology, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Baiba K Gillard†Laboratory of Atherosclerosis and Lipoprotein Research, Department of Cardiology, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Dedipya Yelamanchili†Laboratory of Atherosclerosis and Lipoprotein Research, Department of Cardiology, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Yaliu Yang†Laboratory of Atherosclerosis and Lipoprotein Research, Department of Cardiology, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Harry S Courtney‡Veterans Affairs Medical Center and Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38104, United States.
Raul D Santos§Heart Institute-INCOR, University of Sao Paulo, 05409-003 Sao Paulo, Brazil.
Antonio M Gotto†Laboratory of Atherosclerosis and Lipoprotein Research, Department of Cardiology, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Henry J Pownall†Laboratory of Atherosclerosis and Lipoprotein Research, Department of Cardiology, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
Houston Methodist · USCornell University · USUniversidade de São Paulo · BRUniversity of Tennessee Health Science Center · US

Funding

Therapeutic Approaches to Dysregulated HDL MetabolismR01HL056865 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI POWNALL, HENRY J. · 1997 to 2015
$5.2M
ENZYMIC REACTIONS OF MODEL PLASMA LIPOPROTEINSR01HL030914 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI POWNALL, HENRY J. · 1985 to 2010
$2.2M
NHLBI NIH HHS R01 HL030914NHLBI NIH HHS R01 HL056865NHLBI NIH HHS R01HL056865
6 · The paper itself

Abstract

The reaction of Streptococcal serum opacity factor (SOF) against plasma high-density lipoproteins (HDL) produces a large cholesteryl ester-rich microemulsion (CERM), a smaller neo HDL that is apolipoprotein (apo) AI-poor, and lipid-free apo AI. SOF is active versus both human and mouse plasma HDL. In vivo injection of SOF into mice reduces plasma cholesterol ∼40% in 3 h while forming the same products observed in vitro, but at different ratios. Previous studies supported the hypothesis that labile apo AI is required for the SOF reaction vs HDL. Here we further tested that hypothesis by studies of SOF against HDL from apo AI-null mice. When injected into apo AI-null mice, SOF reduced plasma cholesterol ∼35% in 3 h. The reaction of SOF vs apo AI-null HDL in vitro produced a CERM and neo HDL, but no lipid-free apo. Moreover, according to the rate of CERM formation, the extent and rate of the SOF reaction versus apo AI-null mouse HDL were less than that against wild-type (WT) mouse HDL. Chaotropic perturbation studies using guanidine hydrochloride showed that apo AI-null HDL was more stable than WT HDL. Human apo AI added to apo AI-null HDL was quantitatively incorporated, giving reconstituted HDL. Both SOF and guanidine hydrochloride displaced apo AI from the reconstituted HDL. These results support the conclusion that apo AI-null HDL is more stable than WT HDL because it lacks apo AI, a labile protein that is readily displaced by physicochemical and biochemical perturbations. Thus, apo AI-null HDL is less SOF-reactive than WT HDL. The properties of apo AI-null HDL can be partially restored to those of WT HDL by the spontaneous incorporation of human apo AI. It remains to be determined what other HDL functions are affected by apo AI deletion.

Indexed as

AnimalsApolipoprotein A-IGuanidineHumansLipoproteins, HDLMice, KnockoutPeptide HydrolasesApolipoprotein A-IGuanidineLipoproteins, HDLopacity factorPeptide Hydrolases

Identifiers

PMID25790332
PMCPMC4893950
OpenAlexW1982707898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.